Journal of infection in developing countries · 2024
Profile of co-occurring or secondary infections among COVID-19 patients with HBOT: a single-center retrospective study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Peixia, Wang Hairu, Li Ziyang, Zhang Junyan, Wei Shuang, Xue Zhifeng, Zhang Bozheng, Mei Qi, Wang Zhengtao, Zhao Yani, Niu Qing, Wang Pingzhi
Аннотация
INTRODUCTION: This study was designed to describe the profile of co-occurring or secondary infections in hospitalized coronavirus disease 2019 (COVID-19) patients undergoing hyperbaric oxygen therapy (HBOT) and those without.
METHODOLOGY: Out of 716 COVID-19 patients, 79 cases of co-occurring or secondary infections were included. These patients were categorized into two groups based on their usage of HBOT. The basic information and laboratory examinations, especially pathogen-related results were collected from the medical records. The rate of co-occurring or secondary infections, distribution of pathogens, infection sites, and results of antimicrobial susceptibility testing were analyzed.
RESULTS: Among the 79 COVID-19 patients examined, there were 73 cases of infections, including 58 co-occurring infections, 14 secondary infections, and 1 mixed infection in the non-HBOT group. There were 6 cases with co-occurring or secondary infections in the HBOT group. Influenza virus was predominant in the co-occurring or secondary infections of COVID-19 patients, but it was not detected in patients undergoing HBOT. Klebsiella pneumoniae, Corynebacterium striatum, and Acinetobacter baumannii were the main strains isolated among patients with HBOT. The multidrug-resistant organisms (MDROs) strains of Escherichia coli, Klebsiella aerogenes, Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecium were detected from COVID-19 patients treated with HBOT.
CONCLUSIONS: This study described the profile of in-hospital co-occurring or secondary infections in COVID-19 patients from North China. Management of the co-occurring or secondary infections, especially MDROs infections treated with HBOT, including but not limited to COVID-19, should be strengthened.
METHODOLOGY: Out of 716 COVID-19 patients, 79 cases of co-occurring or secondary infections were included. These patients were categorized into two groups based on their usage of HBOT. The basic information and laboratory examinations, especially pathogen-related results were collected from the medical records. The rate of co-occurring or secondary infections, distribution of pathogens, infection sites, and results of antimicrobial susceptibility testing were analyzed.
RESULTS: Among the 79 COVID-19 patients examined, there were 73 cases of infections, including 58 co-occurring infections, 14 secondary infections, and 1 mixed infection in the non-HBOT group. There were 6 cases with co-occurring or secondary infections in the HBOT group. Influenza virus was predominant in the co-occurring or secondary infections of COVID-19 patients, but it was not detected in patients undergoing HBOT. Klebsiella pneumoniae, Corynebacterium striatum, and Acinetobacter baumannii were the main strains isolated among patients with HBOT. The multidrug-resistant organisms (MDROs) strains of Escherichia coli, Klebsiella aerogenes, Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecium were detected from COVID-19 patients treated with HBOT.
CONCLUSIONS: This study described the profile of in-hospital co-occurring or secondary infections in COVID-19 patients from North China. Management of the co-occurring or secondary infections, especially MDROs infections treated with HBOT, including but not limited to COVID-19, should be strengthened.